Analyst consensus rating
ArriVent BioPharma Analyst Rating: Strong Buy
Direct answer
ArriVent BioPharma's consensus rating is Strong Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $26.20.
Forecast evidence checked November 22, 2026.
Get free ArriVent BioPharma email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $10.52
- Average price target
- $26.20
- High price target
- $29.00
- Low price target
- $22.00
- Low target gap
- +109.1%
- Target upside
- +149%
- High target gap
- +175.7%
- Target range width
- 66.5%
- Consensus rating
- Strong Buy
- Analysts
- 10
- Evidence date
- November 22, 2026
- Valid through
- November 29, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for ArriVent BioPharma?
ArriVent BioPharma has a verified Strong Buy consensus. The same dataset has an average price target of $26.20.
How far are ArriVent BioPharma's low and high targets from the recorded price?
The low target implies +109.1%, while the high target implies +175.7%.
How many analysts are included in ArriVent BioPharma's consensus?
The verified consensus includes 10 analysts.
How is ArriVent BioPharma's target upside or downside calculated?
The average target of $26.20 is divided by the recorded price of $10.52, then one is subtracted to produce +149%. This does not guarantee a future return.
When was ArriVent BioPharma's analyst forecast verified?
The data was verified on 2026-11-22. The dataset is valid through 2026-11-29.